PriceTargets.com logo

Jazz Pharmaceuticals - JAZZ Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $195.67
  • Forecasted Upside: 17.23%
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$166.91 As of 12/4/2025 05:00 PM ET
▼ -0.19 (-0.11%)

This chart shows the closing price for JAZZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Jazz Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JAZZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JAZZ

Analyst Price Target is $195.67
▲ +17.23% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $195.67, with a high forecast of $247.00 and a low forecast of $147.00. The average price target represents a 17.23% upside from the last price of $166.91.

This chart shows the closing price for JAZZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 17 investment analysts is to moderate buy stock in Jazz Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/2/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/26/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/24/2025UBS GroupReiterated RatingBuy ➝ Neutral$163.00 ➝ $188.00
11/24/2025UBS GroupReiterated RatingBuy ➝ Neutral$163.00 ➝ $188.00
11/18/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$170.00 ➝ $235.00
11/18/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$160.00 ➝ $209.00
11/18/2025Bank of AmericaBoost TargetBuy ➝ Buy$230.00 ➝ $247.00
11/17/2025Royal Bank Of CanadaSet TargetOutperform ➝ Outperform$194.00
11/17/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$185.00 ➝ $205.00
11/6/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$151.00 ➝ $155.00
10/27/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$204.00 ➝ $199.00
10/24/2025Morgan StanleySet Target$183.00
10/22/2025Wells Fargo & CompanySet Target$170.00
10/20/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$167.00 ➝ $180.00
10/8/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/27/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/24/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$163.00 ➝ $167.00
8/29/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$162.00 ➝ $185.00
8/28/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$162.00 ➝ $163.00
8/28/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$145.00 ➝ $151.00
8/28/2025Truist FinancialBoost TargetBuy ➝ Buy$200.00 ➝ $205.00
8/28/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$202.00
8/20/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$202.00
8/15/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
8/6/2025Morgan StanleyLower TargetOverweight ➝ Overweight$165.00 ➝ $162.00
7/22/2025Morgan StanleyLower TargetOverweight ➝ Overweight$166.00 ➝ $165.00
7/15/2025Deutsche Bank AktiengesellschaftInitiated CoverageBuy$152.00
6/11/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$202.00
6/3/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$202.00
5/7/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$182.00 ➝ $172.00
5/7/2025Robert W. BairdLower TargetOutperform ➝ Outperform$167.00 ➝ $155.00
5/7/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$176.00 ➝ $147.00
5/7/2025Morgan StanleyLower TargetOverweight ➝ Overweight$183.00 ➝ $166.00
5/7/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
4/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$210.00 ➝ $210.00
3/10/2025HC WainwrightBoost TargetBuy ➝ Buy$200.00 ➝ $217.00
3/7/2025Morgan StanleyReiterated RatingOverweight$175.00 ➝ $183.00
3/7/2025UBS GroupUpgradeNeutral ➝ Buy$145.00 ➝ $179.00
3/6/2025Truist FinancialBoost TargetBuy ➝ Buy$220.00 ➝ $230.00
3/5/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$210.00 ➝ $210.00
2/27/2025BarclaysReiterated RatingOverweight ➝ Overweight$190.00 ➝ $200.00
2/26/2025Cantor FitzgeraldDowngradeOverweight ➝ Neutral$140.00 ➝ $150.00
2/26/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$163.00 ➝ $176.00
2/26/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$179.00 ➝ $178.00
2/26/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$200.00 ➝ $209.00
2/26/2025Needham & Company LLCBoost TargetBuy ➝ Buy$205.00 ➝ $210.00
2/13/2025Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$130.00 ➝ $170.00
12/12/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$163.00 ➝ $163.00
12/12/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$140.00 ➝ $175.00
12/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$207.00 ➝ $207.00
12/10/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$179.00 ➝ $179.00
11/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
11/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$207.00 ➝ $207.00
11/21/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$166.00 ➝ $163.00
11/18/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$154.00 ➝ $162.00
11/7/2024TD CowenLower TargetBuy ➝ Buy$200.00 ➝ $195.00
11/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$207.00 ➝ $207.00
10/23/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$175.00 ➝ $179.00
10/4/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$174.00 ➝ $175.00
9/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$205.00 ➝ $205.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00
8/19/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$190.00 ➝ $202.00
8/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00
8/1/2024Piper SandlerLower TargetOverweight ➝ Overweight$188.00 ➝ $166.00
8/1/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$175.00 ➝ $174.00
8/1/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$140.00 ➝ $120.00
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
8/1/2024Needham & Company LLCLower TargetBuy ➝ Buy$208.00 ➝ $205.00
8/1/2024Robert W. BairdLower TargetOutperform ➝ Outperform$160.00 ➝ $154.00
7/12/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$160.00 ➝ $150.00
7/2/2024UBS GroupLower TargetNeutral ➝ Neutral$117.00 ➝ $113.00
6/20/2024Needham & Company LLCLower TargetBuy ➝ Buy$222.00 ➝ $210.00
6/5/2024The Goldman Sachs GroupInitiated CoverageBuy$169.00
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00
5/3/2024BarclaysLower TargetOverweight ➝ Overweight$230.00 ➝ $200.00
5/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$222.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$180.00
3/22/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$170.00 ➝ $190.00
3/22/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$180.00
3/20/2024Truist FinancialReiterated RatingBuy ➝ Buy$200.00
3/20/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$220.00
3/20/2024Piper SandlerBoost TargetOverweight ➝ Overweight$171.00 ➝ $188.00
3/15/2024Stifel NicolausBoost TargetBuy ➝ Buy$225.00 ➝ $230.00
3/14/2024HC WainwrightLower TargetBuy ➝ Buy$204.00 ➝ $200.00
3/1/2024UBS GroupLower TargetNeutral ➝ Neutral$135.00 ➝ $131.00
3/1/2024BarclaysLower TargetOverweight ➝ Overweight$235.00 ➝ $230.00
2/29/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$180.00
2/29/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$195.00
2/29/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$180.00 ➝ $170.00
2/29/2024Needham & Company LLCLower TargetBuy ➝ Buy$225.00 ➝ $220.00
1/29/2024BarclaysLower TargetOverweight ➝ Overweight$240.00 ➝ $235.00
1/3/2024Robert W. BairdInitiated CoverageOutperform$160.00
12/4/2023Truist FinancialReiterated RatingBuy ➝ Buy$200.00
11/29/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$225.00
11/27/2023UBS GroupDowngradeBuy ➝ Neutral$170.00 ➝ $135.00
11/9/2023Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$200.00 ➝ $191.00
11/9/2023Needham & Company LLCLower TargetBuy ➝ Buy$226.00 ➝ $225.00
9/28/2023Raymond James FinancialInitiated CoverageMarket Perform
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$180.00
8/14/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$210.00 ➝ $180.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$204.00
8/10/2023Bank of AmericaBoost TargetBuy ➝ Buy$204.00 ➝ $217.00
8/10/2023Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$203.00 ➝ $201.00
8/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$226.00
7/10/2023Cantor FitzgeraldReiterated RatingOverweight
5/11/2023Royal Bank Of CanadaLower Target$207.00 ➝ $202.00
5/11/2023Needham & Company LLCBoost Target$205.00 ➝ $212.00
3/6/2023HC WainwrightReiterated RatingBuy$204.00
3/3/2023The Goldman Sachs GroupBoost TargetBuy$190.00 ➝ $212.00
3/2/2023Needham & Company LLCLower TargetBuy$210.00 ➝ $205.00
12/8/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$192.00 ➝ $190.00
11/10/2022The Goldman Sachs GroupBoost TargetNeutral$170.00 ➝ $192.00
11/10/2022Royal Bank Of CanadaBoost TargetOutperform$206.00 ➝ $207.00
11/10/2022Needham & Company LLCLower TargetBuy$210.00 ➝ $208.00
9/29/2022The Goldman Sachs GroupBoost TargetNeutral$148.00 ➝ $170.00
9/21/2022The Goldman Sachs GroupLower TargetNeutral$192.00 ➝ $148.00
8/5/2022HC WainwrightLower Target$210.00 ➝ $204.00
8/4/2022BMO Capital MarketsBoost TargetOutperform$185.00 ➝ $188.00
8/4/2022Leerink PartnersBoost TargetOutperform$200.00 ➝ $210.00
8/4/2022UBS GroupLower TargetBuy$194.00 ➝ $191.00
8/4/2022Morgan StanleyBoost TargetEqual Weight$174.00 ➝ $187.00
6/13/2022UBS GroupInitiated CoverageBuy$194.00
5/5/2022CowenBoost Target$200.00 ➝ $225.00
5/5/2022CowenBoost Target$200.00 ➝ $225.00
5/5/2022Piper SandlerLower Target$197.00 ➝ $193.00
4/6/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$202.00 ➝ $196.00
3/3/2022HC WainwrightBoost TargetBuy$210.00 ➝ $215.00
3/2/2022Cantor FitzgeraldReiterated RatingOverweight
3/2/2022Piper SandlerLower TargetOverweight$209.00 ➝ $197.00
3/2/2022Royal Bank Of CanadaLower TargetOutperform$216.00 ➝ $214.00
3/2/2022BMO Capital MarketsLower Target$202.00 ➝ $187.00
2/7/2022Needham & Company LLCReiterated RatingBuy$215.00
1/20/2022Truist FinancialBoost Target$180.00 ➝ $200.00
12/20/2021Leerink PartnersLower TargetOutperform$230.00 ➝ $200.00
12/17/2021Needham & Company LLCLower TargetBuy$220.00 ➝ $215.00
11/18/2021The Goldman Sachs GroupInitiated CoverageBuy
10/8/2021Morgan StanleyLower TargetEqual Weight$176.00 ➝ $174.00
10/5/2021CitigroupInitiated CoverageBuy$200.00
9/22/2021Needham & Company LLCInitiated CoverageBuy$220.00
8/16/2021HC WainwrightLower TargetBuy$220.00 ➝ $210.00
7/23/2021Royal Bank Of CanadaBoost TargetOutperform$190.00 ➝ $216.00
7/22/2021Leerink PartnersReiterated RatingBuy
7/6/2021Jefferies Financial GroupInitiated CoverageBuy$220.00
6/22/2021BarclaysBoost TargetOverweight$235.00 ➝ $250.00
6/21/2021HC WainwrightBoost TargetBuy$212.00 ➝ $220.00
6/18/2021Leerink PartnersBoost TargetOutperform$210.00 ➝ $230.00
5/24/2021Piper SandlerReiterated RatingBuy$214.00
5/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight
5/17/2021HC WainwrightBoost TargetBuy$207.00 ➝ $212.00
5/9/2021Leerink PartnersReiterated RatingBuy
5/7/2021Jefferies Financial GroupReiterated RatingBuy
4/21/2021Cantor FitzgeraldBoost TargetOverweight$185.00 ➝ $198.00
4/14/2021Stifel NicolausBoost TargetBuy$195.00 ➝ $202.00
4/1/2021Morgan StanleyBoost TargetEqual Weight$162.00 ➝ $176.00
3/15/2021Leerink PartnersReiterated RatingOutperform
3/1/2021UBS GroupBoost TargetBuy$174.00 ➝ $228.00
2/25/2021Leerink PartnersLower TargetOutperform$213.00 ➝ $210.00
2/24/2021CowenBoost TargetOutperform$190.00 ➝ $200.00
2/24/2021Jefferies Financial GroupBoost TargetBuy$209.00 ➝ $214.00
2/24/2021Piper SandlerBoost TargetOverweight$175.00 ➝ $205.00
2/5/2021HC WainwrightBoost TargetBuy$195.00 ➝ $207.00
2/3/2021Piper SandlerUpgradeNeutral ➝ Overweight$150.00 ➝ $175.00
1/29/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$177.00 ➝ $162.00
12/15/2020UBS GroupInitiated CoverageBuy$174.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.02 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 40 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 27 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
7/7/2025
  • 23 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 47 very positive mentions
  • 30 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 44 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 5 very negative mentions
Mentions as of
10/5/2025
  • 25 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 51 very positive mentions
  • 38 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 51 very positive mentions
  • 38 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $166.91
Low: $164.44
High: $167.30

50 Day Range

MA: $146.99
Low: $127.00
High: $180.90

52 Week Range

Now: $166.91
Low: $95.49
High: $182.99

Volume

844,967 shs

Average Volume

1,579,805 shs

Market Capitalization

$10.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Jazz Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Jazz Pharmaceuticals in the last twelve months: Bank of America Corporation, Barclays PLC, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for JAZZ.

What is the current price target for Jazz Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Jazz Pharmaceuticals in the last year. Their average twelve-month price target is $195.67, suggesting a possible upside of 17.2%. Bank of America Corporation has the highest price target set, predicting JAZZ will reach $247.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $147.00 for Jazz Pharmaceuticals in the next year.
View the latest price targets for JAZZ.

What is the current consensus analyst rating for Jazz Pharmaceuticals?

Jazz Pharmaceuticals currently has 1 sell rating, 3 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for JAZZ.

What other companies compete with Jazz Pharmaceuticals?

Other companies that are similar to Jazz Pharmaceuticals include Axsome Therapeutics, Royalty Pharma, Corcept Therapeutics, Supernus Pharmaceuticals and Perrigo. Learn More about companies similar to Jazz Pharmaceuticals.

How do I contact Jazz Pharmaceuticals' investor relations team?

Jazz Pharmaceuticals' physical mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company's listed phone number is (531) 634-7800 and its investor relations email address is [email protected]. The official website for Jazz Pharmaceuticals is www.jazzpharma.com. Learn More about contacing Jazz Pharmaceuticals investor relations.